Cabozantinib (Cometriq)

General information

Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Hepatocellular carcinoma
• Non-small cell lung cancer
• Prostate cancer
• Renal cell carcinoma
• Medullary thyroid cancer

Patient drug information

• Cabozantinib (Cometriq) package insert pages 20-24 (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
• Cabozantinib (Cabometyx) package insert
• Cabozantinib (Cometriq) patient drug information (Chemocare)
• Cabozantinib (Cometriq) patient drug information (UpToDate)

History of changes in FDA indication

• 11/29/2012: FDA approved (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC).
• 4/25/2016: FDA approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
• 12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC).

Also known as

• Code names: XL184, XL-184
• Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.